Periodical
Real-World Outcomes Following Dose Modifications of First-Line Ibrutinib in Patients with Waldenström Macroglobulinemia
| العنوان: | Real-World Outcomes Following Dose Modifications of First-Line Ibrutinib in Patients with Waldenström Macroglobulinemia |
|---|---|
| المؤلفون: | Sarosiek, Shayna R, von Keudell, Gottfried R., Paludo, Jonas, Salkar, Monika, Agatep, Barnabie, Franco, Anjali, Crawford, Samuel, Pacia, Michelle, Castillo, Jorge J. |
| المصدر: | Blood; November 2023, Vol. 142 Issue: 1, Number 1 Supplement 1 p3780-3780, 1p |
| مستخلص: | Background:In patients with Waldenström macroglobulinemia (WM), continuous once-daily ibrutinib-based therapy has been associated with long-term progression-free survival. In addition, patients who continued ibrutinib-based treatment had better survival outcomes than those who discontinued treatment within the first few years. Evidence based on a single-center retrospective study suggests that dose reduction (DR) can be used to effectively manage ibrutinib-related adverse events (AEs) and avoid early treatment discontinuation. However, real-world data on outcomes in patients with WM after ibrutinib DR are limited. In this real-world study, we analyzed short-term (1-year follow-up) dosing patterns and time to treatment discontinuation (TTD) in patients with WM, with and without DR, who were receiving first-line (1L) ibrutinib. |
| قاعدة البيانات: | Supplemental Index |
Full Text Finder | تدمد: | 00064971 15280020 |
|---|---|
| DOI: | 10.1182/blood-2023-181925 |